To read the full story, subscribe or sign in.

Neurogene slides on Rett syndrome gene therapy safety concern

Nov. 18, 2024

Neurogene Inc.’s stock sank 43% on news that its phase I/II gene therapy, NGN-401, resulted in a serious adverse event in a pediatric Rett syndrome patient receiving the highest dose.

BioWorld Clinical Neurology/psychiatric Gene therapy U.S.

Today's news in brief

BioWorld

BioWorld briefs for April 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 10, 2025.

mRNA-based vaccine is immunogenic, protective in Lyme disease

BioWorld Science

Lyme disease is a multisystemic zoonotic infection caused by Borrelia burgdorferi bacteria transmitted by ticks. Lyme disease is a public health problem because...

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Alzheon’s lead candidate misses a phase III in early Alzheimer’s

BioWorld

Alzheon Inc.’s oral treatment for people in the early stages of Alzheimer’s disease missed its phase III primary endpoint, adding yet another therapy to a long...